Erasca (NASDAQ:ERAS) is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.
Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling. Among these are selective RAF dimer inhibitors and pan‐RAF inhibitors, which are being evaluated in various solid tumors harboring KRAS and BRAF mutations. The company employs a translational research strategy that integrates preclinical modeling, biomarker identification and early clinical proof‐of‐concept studies, enabling efficient progression of assets from the lab to first‐in‐human trials.
Headquartered in San Diego, California, Erasca conducts its research and development activities in collaboration with leading academic institutions and clinical sites across North America and Europe. By leveraging a global network of investigators and trial centers, the company advances its candidates through multi‐site clinical studies, gathering data on safety, pharmacokinetics and preliminary efficacy in diverse patient populations.
Founded in 2016, Erasca is led by Jack Bailey, Chief Executive Officer, who brings more than two decades of experience in oncology research and drug development. The company’s leadership team combines expertise in medicinal chemistry, translational biology and clinical operations, positioning Erasca to advance its mission of delivering innovative cancer therapies to patients worldwide.
